“The industry might do itself a favor by not trying to set record pricing for every drug that gets approved. Maybe throttle back a little bit. That might be a good idea.”

Biotech Hangout · Health & Longevity · November 2026

Context

Weighing whether the new Congress will act on drug prices, he makes a pointed aside about the industry's own launch-pricing behavior.

Listen to the episode → More from Adam Feuerstein → More Health & Longevity quotes →

Transcript

Biotech Hangout Around 15:31 into the episode

Paul Matteis

…leadership at the same time. Like, I don't know. And then, just in the backdrop of that, like, how long is the Senate in session between now and January 20th? And is this even like a top priority? So, I have to wonder if like the FDA commissioner stuff could drag on from uncertainty for some time.

Brian Skorney

…up. A lot of new investment will be freed up. So I think it's a net positive, but like I do think we're in for some noise over the next couple of months. And I also agree with your own that like the macro and the interest rates and spending outside of biotech can have a material impact there. So

Adam Feuerstein

I mean, the industry, the industry might do itself a favor by not trying to set record pricing for every drug that gets approved. You know, like maybe, you know, throttled back a little bit. That might be a good idea.

Paul Matteis

Maybe. We've been having this conversation for like 20 years, right? Keep doing it. I know. I know, but

Adam Feuerstein

it just seems, it just seems like, it just seems like it's gotten worse. I don't know. No,

Paul Matteis

yeah, I didn't mean to imply that it wasn't people's own doing. I think you're right, Adam. Like, it's kind of crazy. Okay. So, so I think let's move on from some of

Speaker names come from our own diarization. The position is estimated from where the line sits in the episode.

More from Biotech Hangout

“I always have a hard time getting all that excited about a gene therapy program for a disease that has other good therapeutic alternatives or doesn't have some morbidity and mortality to it. … To me, it's just reaffirming that AAV right now feels like it's a rare disease modality. And going more broadly, develop elsewhere at your own peril is sort of how it feels.” — Paul Matteis, Biotech Hangout

“What I find fascinating about all this is that this is the first time since hepatitis C that Vertex has to compete in a market. … Vertex has never really had to work for their supper, so to speak. And here they have two very formidable competitors with drugs that seem to help patients quite a bit. There's not a lot of daylight between these three drugs. And here they are, coming in third to market with less data.” — Adam Feuerstein, Biotech Hangout